ClinicalTrials.gg
CompletedNCT05313802Updated May 26, 2026Results posted

A Study of LY3502970 in Healthy Overweight and Obese Participants

A Phase 1 interventional study of LY3502970 in Healthy and Obese, sponsored by Eli Lilly and Company. Completed at 3 sites in United States. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-26.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 22 studies testing orforglipron in Obesity — 4 open to participants now, 10 under way, 9 of them phase 3. orforglipron · Obesity.

Enrollment
18th of 22
72 · median 324
Started
2022
the only one that year
Phase 1
6 of 22
none open now
Registered
2nd of 22
by date
Lead sponsor
21 of 22
Eli Lilly and Company

Among the 22 studies testing orforglipron in Obesity, this one is the 18th largest by enrollment, is the only one that started in 2022, is one of 6 in phase 1, and was the 2nd registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.

Browse Obesity studies →

Open to participants now

4 of the 22 studies testing orforglipron in Obesity are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About orforglipron

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,339 Obesity studies recruiting now, 377 (28%) set no upper age limit and 859 (64%) stop at 75 or younger; 167 take children under 18; 490 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing orforglipron in Obesity, or all of them as a file.
02

Study summary

The main purpose of this study is to evaluate the safety and tolerability of LY3502970 in healthy overweight and obese participants. The blood tests will be conducted to measure how much LY3502970 is in the bloodstream and how the body handles and eliminates LY3502970 in these participants. The study will last up to 42 days excluding the screening period.

03

Conditions studied

  • Healthy
  • Obese

Browse trials for

Keywords

  • Pharmacokinetics
  • Safety and Tolerability
  • LY3502970
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with stable body weight for at least one month prior to randomization.
  • Participants with (BMI) of greater than or equal to (≥) 27.0 kilograms per meter squared (kg/m²)
  • Male participants who agree to use highly effective/effective methods of and female participants not of

Exclusion criteria

Exclusion Criteria:

  • Have known allergies to LY3502970 or other glucagon-like peptide-1 Receptor Agonists (GLP-1 RA) analogs
  • Significant history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological or neurological disorders
  • Have any type of diabetes with (HbA1c) ≥6.5 %
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
72 participants (actual)

Study arms

  • Experimental
    LY3502970 Cohort 1

    Participants received oral doses of 2 milligrams (mg) LY3502970 from days 1-14 and 3 mg LY3502970 from days 15-28 once daily (QD).

    Drug: LY3502970

  • Experimental
    LY3502970 Cohort 2

    Participants received oral doses of 1 mg LY3502970 from days 1-7, 2 mg LY3502970 from days 8-21 and 3 mg LY3502970 from days 22-28 QD.

    Drug: LY3502970

  • Experimental
    LY3502970 Cohort 3

    Participants received oral doses of 1 mg LY3502970 from days 1-14, 2 mg LY3502970 from days 15-21 and 3 mg LY3502970 from days 22-28 QD.

    Drug: LY3502970

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration

    A TEAE is an untoward medical occurrence that emerges during a defined treatment period, having been absent pretreatment, or worsens relative to the pretreatment state, and does not necessarily have to have a causal relationship with this treatment. An SAE is any adverse event from this study that results in one of the following: Death, initial or prolonged inpatient hospitalization, a life-threatening experience, persistent or significant disability/incapacity, congenital anomaly/birth defect, important medical events that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the participant or may require intervention to prevent one of the other outcomes listed in the definition above. An overall summary of SAEs and other non-serious adverse events, regardless of causality, will be reported in the Reported Adverse Events module.

    Time frame: Baseline up to Day 42

Secondary outcomes

  1. Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to the Last Measurable Concentration (AUC[0-tlast]) of LY3502970 on Day 1

    PK: AUC\[0-tlast\] of LY3502970

    Time frame: Day 1 (Pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16 and 24 hours post-dose)

  2. PK: Maximum Observed Concentration (Cmax) of LY3502970 on Day 1

    PK: Cmax of LY3502970

    Time frame: Day 1 (Pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16 and 24 hours post-dose)

  3. PK: Time to Maximum Observed Concentration (Tmax) of LY3502970 on Day 1

    PK: Tmax of LY3502970

    Time frame: Day 1 (Pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16 and 24 hours post-dose)

  4. PK: AUC[0-tlast] of LY3502970 on Day 28

    PK: AUC\[0-tlast\] of LY3502970

    Time frame: Day 28 (Pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16 and 24 hours post-dose)

  5. PK: Cmax of LY3502970 on Day 28

    PK: Cmax of LY3502970

    Time frame: Day 28 (Pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16 and 24 hours post-dose)

  6. PK: Tmax of LY3502970 on Day 28

    PK: Tmax of LY3502970

    Time frame: Day 28 (Pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16 and 24 hours post-dose)

  7. Pharmacodynamics (PD): Change From Baseline in Body Weight

    PD: Change From Baseline in Body Weight

    Time frame: Baseline through Day 29

07

Results

Posted May 26, 2026

Participant flow

Participant flow — Overall Study
MilestoneLY3502970 Cohort 1LY3502970 Cohort 2LY3502970 Cohort 3
Started242424
Received at least one dose of study drug242424
Ly3502970 - 1 mg02424
Ly3502970 - 2 mg242423
Ly3502970 - 3 mg242422
Completed242322
Not completed012
Withdrew: Adverse event011
Withdrew: Withdrawal by subject001

Outcome measures

PrimaryNumber of Participants With One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration

A TEAE is an untoward medical occurrence that emerges during a defined treatment period, having been absent pretreatment, or worsens relative to the pretreatment state, and does not necessarily have to have a causal relationship with this treatment. An SAE is any adverse event from this study that results in one of the following: Death, initial or prolonged inpatient hospitalization, a life-threatening experience, persistent or significant disability/incapacity, congenital anomaly/birth defect, important medical events that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the participant or may require intervention to prevent one of the other outcomes listed in the definition above. An overall summary of SAEs and other non-serious adverse events, regardless of causality, will be reported in the Reported Adverse Events module.

Time frame:
Baseline up to Day 42
Reported as:
Number · participants
Number of Participants With One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
participantsLY3502970 Cohort 1LY3502970 Cohort 2LY3502970 Cohort 3
Number of Participants With One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration202116
SecondaryPharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to the Last Measurable Concentration (AUC[0-tlast]) of LY3502970 on Day 1

PK: AUC\[0-tlast\] of LY3502970

Time frame:
Day 1 (Pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16 and 24 hours post-dose)
Reported as:
Geometric mean · nanogram hour per milliliter (ng*h/mL)
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to the Last Measurable Concentration (AUC[0-tlast]) of LY3502970 on Day 1
nanogram hour per milliliter (ng*h/mL)LY3502970 Cohort 1LY3502970 Cohort 2LY3502970 Cohort 3
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to the Last Measurable Concentration (AUC[0-tlast]) of LY3502970 on Day 1117 ± 3966.1 ± 2566.9 ± 30
SecondaryPK: Maximum Observed Concentration (Cmax) of LY3502970 on Day 1

PK: Cmax of LY3502970

Time frame:
Day 1 (Pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16 and 24 hours post-dose)
Reported as:
Geometric mean · nanograms per milliliter (ng/mL)
PK: Maximum Observed Concentration (Cmax) of LY3502970 on Day 1
nanograms per milliliter (ng/mL)LY3502970 Cohort 1LY3502970 Cohort 2LY3502970 Cohort 3
PK: Maximum Observed Concentration (Cmax) of LY3502970 on Day 18.40 ± 414.97 ± 255.00 ± 34
SecondaryPK: Time to Maximum Observed Concentration (Tmax) of LY3502970 on Day 1

PK: Tmax of LY3502970

Time frame:
Day 1 (Pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16 and 24 hours post-dose)
Reported as:
Median · hours (h)
PK: Time to Maximum Observed Concentration (Tmax) of LY3502970 on Day 1
hours (h)LY3502970 Cohort 1LY3502970 Cohort 2LY3502970 Cohort 3
PK: Time to Maximum Observed Concentration (Tmax) of LY3502970 on Day 17.03 (4.00 to 8.00)6.00 (4.00 to 8.00)6.00 (4.00 to 8.00)
SecondaryPK: AUC[0-tlast] of LY3502970 on Day 28

PK: AUC\[0-tlast\] of LY3502970

Time frame:
Day 28 (Pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16 and 24 hours post-dose)
Reported as:
Geometric mean · ng*h/mL
PK: AUC[0-tlast] of LY3502970 on Day 28
ng*h/mLLY3502970 Cohort 1LY3502970 Cohort 2LY3502970 Cohort 3
PK: AUC[0-tlast] of LY3502970 on Day 28275 ± 40277 ± 34314 ± 26
SecondaryPK: Cmax of LY3502970 on Day 28

PK: Cmax of LY3502970

Time frame:
Day 28 (Pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16 and 24 hours post-dose)
Reported as:
Geometric mean · ng/mL
PK: Cmax of LY3502970 on Day 28
ng/mLLY3502970 Cohort 1LY3502970 Cohort 2LY3502970 Cohort 3
PK: Cmax of LY3502970 on Day 2818.4 ± 4318.4 ± 4121.2 ± 35
SecondaryPK: Tmax of LY3502970 on Day 28

PK: Tmax of LY3502970

Time frame:
Day 28 (Pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16 and 24 hours post-dose)
Reported as:
Median · h
PK: Tmax of LY3502970 on Day 28
hLY3502970 Cohort 1LY3502970 Cohort 2LY3502970 Cohort 3
PK: Tmax of LY3502970 on Day 286.00 (4.00 to 12.00)6.00 (4.00 to 12.00)6.00 (4.00 to 8.00)
SecondaryPharmacodynamics (PD): Change From Baseline in Body Weight

PD: Change From Baseline in Body Weight

Time frame:
Baseline through Day 29
Reported as:
Mean · kilograms (kg)
Pharmacodynamics (PD): Change From Baseline in Body Weight
kilograms (kg)LY3502970 Cohort 1LY3502970 Cohort 2LY3502970 Cohort 3
Pharmacodynamics (PD): Change From Baseline in Body Weight-4.2 ± 2.5-5.5 ± 3.5-3.6 ± 1.9

Adverse events

Collected over Baseline Through End of Safety Follow-Up (Up To Day 42). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
LY3502970 Cohort 10/24 (0%)0/24 (0%)19/24 (79.2%)
LY3502970 Cohort 20/24 (0%)0/24 (0%)20/24 (83.3%)
LY3502970 Cohort 30/24 (0%)0/24 (0%)13/24 (54.2%)
Most frequent other events
Showing 10 of 12
Most frequent other events
EventLY3502970 Cohort 1LY3502970 Cohort 2LY3502970 Cohort 3
DyspepsiaGastrointestinal disorders4/2410/246/24
ConstipationGastrointestinal disorders9/248/246/24
HeadacheNervous system disorders8/245/244/24
Weight decreasedInvestigations6/247/243/24
NauseaGastrointestinal disorders4/246/242/24
DiarrhoeaGastrointestinal disorders4/245/242/24
VomitingGastrointestinal disorders2/244/241/24
EructationGastrointestinal disorders2/240/243/24
Gastrooesophageal reflux diseaseGastrointestinal disorders3/240/241/24
Abdominal distensionGastrointestinal disorders1/241/242/24

Baseline characteristics

All enrolled participants who received at least one dose of study drug.

Age, Continuous
Age, Continuous(years)LY3502970 Cohort 1LY3502970 Cohort 2LY3502970 Cohort 3Total
Mean41.8 ± 14.142.3 ± 13.446.1 ± 14.843.4 ± 14.1
Sex: Female, Male
Sex: Female, Male(Participants)LY3502970 Cohort 1LY3502970 Cohort 2LY3502970 Cohort 3Total
Female5111026
Male19131446
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)LY3502970 Cohort 1LY3502970 Cohort 2LY3502970 Cohort 3Total
Hispanic or Latino1410933
Not Hispanic or Latino10141539
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)LY3502970 Cohort 1LY3502970 Cohort 2LY3502970 Cohort 3Total
American Indian or Alaska Native0000
Asian0033
Native Hawaiian or Other Pacific Islander1001
Black or African American311418
White20111748
More than one race0202
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(Participants)LY3502970 Cohort 1LY3502970 Cohort 2LY3502970 Cohort 3Total
United States24242472
08

Study locations

3 sites
  • Qps-Mra, Llc
    Miami, Florida 33143, United States
  • ICON Early Phase Services Lenexa Center
    Lenexa, Kansas 66219, United States
  • ICON Early Phase Services
    San Antonio, Texas 78209, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2022 to primary completion in Sep 2022, 3 months.

Results were first posted in May 2026, 3 years 8 months after primary completion.

Of 334 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 3 months is below that.

Counting every sponsor, half of 439 studies reached it within 11 months; a quarter within 6 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 4, 2022
First posted
Apr 6, 2022
StartActual
May 26, 2022
Primary completionActual
Sep 9, 2022
CompletionActual
Sep 9, 2022
Results first posted
May 26, 2026
Last update
May 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05313802
Responsible party
Sponsor
First posted
Apr 6, 2022
Start date
May 26, 2022
Primary completion
Sep 9, 2022
Completion
Sep 9, 2022
Results posted
May 26, 2026
Last update
May 26, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Orforglipron

Start the discussion